Gyre Therapeutics Inc (NASDAQ: GYRE) is a biopharmaceutical company focused on organ fibrosis and related inflammatory diseases, operating primarily in the People's Republic of China. The company generates revenue by commercializing approved pharmaceutical products in the PRC while simultaneously advancing a clinical and preclinical pipeline targeting fibrosis, pulmonary arterial hypertension, and chronic obstructive pulmonary disease. Gyre Pharmaceuticals, its PRC operating subsidiary, maintains in-house manufacturing capabilities across two production centers and a nationwide sales network. As of December 31, 2025, the company employed 618 people in the PRC, with 403 in sales and marketing roles spread across the country. Pipeline assets include Hydronidone, a drug candidate for organ fibrosis currently in a Phase 3c confirmatory clinical trial under a RMB 114.0 million (approximately $16.2 million as of December 31, 2025) CRO agreement; F230, a selective endothelin receptor A antagonist for pulmonary arterial hypertension that entered Phase 1 in June 2025; and F528, a preclinical anti-inflammatory compound targeting COPD with an IND submission anticipated in the first quarter of 2027.

Revenue model

Revenue is generated through commercial sales of approved pharmaceutical products in the PRC, supported by an in-house manufacturing operation and a direct sales force. Pipeline programs are funded through equity financing and are not yet revenue-generating; clinical development expenditures include milestone-based payments to contract research organizations.

Products and services

Approved and commercial-stage products sold in the PRC through Gyre Pharmaceuticals; Hydronidone capsules (organ fibrosis, Phase 3c confirmatory trial ongoing as of December 2025); F230 selective endothelin receptor A antagonist (PAH, Phase 1 as of June 2025); F528 anti-inflammatory small molecule (COPD, preclinical as of December 31, 2025).

Customers and end markets

Patients and healthcare providers in the PRC treated for organ fibrosis, pulmonary arterial hypertension, and chronic inflammatory respiratory conditions. Distribution is through a nationwide sales network targeting hospitals and prescription drug programs across China.

Value-chain role

Vertically integrated within the PRC: internal drug discovery and screening, in-house manufacturing at two production centers, and a direct commercial sales force. Clinical development is partially outsourced to third-party CROs for later-stage trials.

Geographic exposure

Operations concentrated in the People's Republic of China. Corporate headquarters and R&D activities include a presence in Beijing (172 employees as of December 31, 2025) and a manufacturing center in Cangzhou (43 employees as of December 31, 2025), with 403 additional employees in other PRC regions primarily in sales and marketing. The company is listed on a U.S. exchange and subject to SEC reporting.

Source: SEC 10-K, filed 2026-03-13

Industry: Pharmaceutical Preparations Peers: Aprea Therapeutics Inc Aridis Pharmaceuticals, Inc. Axim Biotechnologies Inc Old Ayala, Inc Soleno Therapeutics Inc Innovation Pharmaceuticals Inc. Cyclo Therapeutics, Inc. Bio Green Med Solution Inc